Zymeworks (NASDAQ:ZYME) Shares Down 6.6% – Here’s Why

Posted by Brian Himes on Nov 11th, 2026

Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) shares were down 6.6% on Wednesday. The company traded as low as $28.98 and last traded at $29.38. Approximately 76,148 shares were traded during trading, a decline of 90% from the average daily volume of 780,271 shares. The stock had previously closed at $31.46.

Zymeworks News Summary

Here’s some of the latest news about ZYME:

Positive Sentiment: Higher 2026 earnings guidance: Zymeworks raised its earnings outlook for the year, supporting the investment case. Zymeworks raises 2026 earnings guidance
Positive Sentiment: Analyst targets increased: TD Cowen raised its target to $39, Truist Financial to $36, and HC Wainwright to $56; all retained Buy ratings. These revisions indicate greater analyst optimism. TD Cowen rating
Neutral Sentiment: EPS estimates were mixed: Zymeworks reported $2.28 per share—slightly above one consensus estimate of $2.27, but below Zacks’ $2.40 estimate. This leaves the earnings-per-share read less uniformly positive than the revenue result. Zacks earnings report

Analyst Ratings Changes

Several analysts have weighed in on ZYME shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research report on Thursday, October 15th. Wells Fargo & Company increased their target price on Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft set a $32.00 target price on Zymeworks in a research note on Wednesday, August 26th. Truist Financial upped their price target on Zymeworks from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, B. Riley Financial reissued a “buy” rating and set a $44.00 price objective (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Read Our Latest Stock Report on Zymeworks

Zymeworks Stock Performance

The company has a market capitalization of $2.07 billion, a PE ratio of 56.63 and a beta of 1.32. The company’s 50-day moving average is $27.50 and its 200 day moving average is $25.42.

Zymeworks (NASDAQ:ZYME – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 25.07%. The business had revenue of $512.92 million during the quarter, compared to analysts’ expectations of $227.40 million. During the same period in the previous year, the company earned ($0.26) earnings per share. The business’s revenue for the quarter was up 828.7% compared to the same quarter last year. On average, analysts forecast that Zymeworks Inc. will post 1.32 EPS for the current fiscal year.

Insider Buying and Selling

In other Zymeworks news, EVP Adam Schayowitz sold 13,832 shares of Zymeworks stock in a transaction on Friday, October 9th. The stock was sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the sale, the executive vice president owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 37.73% of the company’s stock.

Institutional Investors Weigh In On Zymeworks

Several large investors have recently bought and sold shares of the business. Janney Montgomery Scott LLC boosted its holdings in shares of Zymeworks by 3.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 11,487 shares of the company’s stock valued at $288,000 after acquiring an additional 420 shares during the last quarter. Tema ETFs LLC raised its holdings in shares of Zymeworks by 0.7% during the second quarter. Tema ETFs LLC now owns 105,615 shares of the company’s stock valued at $2,761,000 after purchasing an additional 684 shares during the last quarter. Tidal Investments LLC lifted its position in Zymeworks by 0.7% during the second quarter. Tidal Investments LLC now owns 105,615 shares of the company’s stock valued at $2,761,000 after purchasing an additional 684 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Zymeworks by 10.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,507 shares of the company’s stock worth $221,000 after purchasing an additional 800 shares during the last quarter. Finally, Nykredit A S purchased a new stake in Zymeworks in the second quarter worth approximately $25,000. 92.89% of the stock is currently owned by institutional investors.

About Zymeworks

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.